Drugs / MBS301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03842085 | Apr 2019 → Dec 2024 overdue | HER2 positive breast carcinoma | Beijing Mabworks Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBS301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03842085 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Bispecific Monoclonal Antibody MBS301” NCT03842085 ↗ |
| Route | Intravenous | “after intravenous administration” NCT03842085 ↗ |